Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-221636
, Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data.., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-221636
Retrospective 1,606 SLE patients showing lower risk of severe COVID-19 outcomes with HCQ/CQ use.
|
risk of severe case, 44.4% lower, OR 0.56, p = 0.007, treatment 665, control 230, adjusted per study, inverted to make OR<1 favor treatment, HCQ/CQ only vs. no SLE medication, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ugarte-Gil et al., 16 Feb 2022, retrospective, multiple countries, peer-reviewed, 58 authors.
Abstract: EPIDEMIOLOGICAL SCIENCE
Characteristics associated with poor COVID-19
outcomes in individuals with systemic lupus
erythematosus: data from the COVID-19 Global
Rheumatology Alliance
Handling editor Josef S
Smolen
► Additional supplemental
material is published online
only. To view, please visit the
journal online (http://d x.doi.
org/1 0.1136/a nnrheumdis-
2021-221636).
For numbered affiliations see
end of article.
Correspondence to
Manuel Francisco Ugarte-Gil,
Universidad Cientifica del Sur,
Miraflores, Peru;
mugarte@cientifica.e du.pe
Received 8 October 2021
Accepted 14 January 2022
© Author(s) (or their
employer(s)) 2022. No
commercial re-use. See rights
and permissions. Published
by BMJ.
To cite: Ugarte-Gil MF,
Alarcón GS, Izadi Z, et al.
Ann Rheum Dis Epub ahead
of print: [please include Day
Month Year]. doi:10.1136/
annrheumdis-2021-221636
Manuel Francisco Ugarte-Gil ,1,2 Graciela S Alarcón ,3,4 Zara Izadi ,5,6
Ali Duarte-García ,7,8 Cristina Reátegui-Sokolova ,2,9 Ann Elaine Clarke,10
Leanna Wise,11 Guillermo J Pons-Estel ,12,13 Maria Jose Santos ,14,15
Sasha Bernatsky ,16 Sandra Lúcia Euzébio Ribeiro ,17 Samar Al Emadi ,18
Jeffrey A Sparks ,19 Tiffany Y -T Hsu ,19 Naomi J Patel,20 Emily L Gilbert,21
Maria O Valenzuela-Almada,7 Andreas Jönsen,22 Gianpiero Landolfi,23
Micaela Fredi,24,25 Tiphaine Goulenok,26,27 Mathilde Devaux,28 Xavier Mariette ,29
Viviane Queyrel,30 Vasco C Romão ,31,32 Graca Sequeira,33 Rebecca Hasseli,34
Bimba Hoyer,35 Reinhard E Voll,36 Christof Specker ,37 Roberto Baez,38
Vanessa Castro-Coello,39 Hernan Maldonado Ficco,40 Edgard Torres Reis Neto ,41
Gilda Aparecida Aparecida Ferreira ,42,43 Odirlei Andre André Monticielo ,44,45
Emily Sirotich ,46,47 Jean Liew,48 Jonathan Hausmann ,49,50 Paul Sufka,51
Rebecca Grainger,52 Suleman Bhana,53 Wendy Costello,54 Zachary S Wallace,20
Lindsay Jacobsohn,6 Tiffany Taylor,6 Clairissa Ja,6 Anja Strangfeld ,55
Elsa F Mateus ,56,57 Kimme L Hyrich ,58,59 Loreto Carmona ,60
Saskia Lawson-Tovey ,59,61 Lianne Kearsley-Fleet ,62 Martin Schäfer ,63
Pedro M Machado ,64,65,66,67 Philip C Robinson ,68,69 Milena Gianfrancesco,6
Jinoos Yazdany6
ABSTRACT
Aim To determine characteristics associated with more
severe outcomes in a global registry of people with
systemic lupus erythematosus (SLE) and COVID-19.
Methods People with SLE and COVID-19 reported in
the COVID-19 Global Rheumatology Alliance registry
from March 2020 to June 2021 were included. The
ordinal outcome was defined as: (1) not hospitalised,
(2) hospitalised with no oxygenation, (3) hospitalised
with any ventilation or oxygenation and (4) death.
A multivariable ordinal logistic regression model
was constructed to assess the relationship between
COVID-19 severity and demographic characteristics,
comorbidities, medications and disease activity.
Results A total of 1606 people with SLE were included.
In the multivariable model, older age (OR 1.03, 95% CI
1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone
dose (1–5 mg/day 1.86, 1.20 to 2.66, 6–9 mg/day 2.47,
1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no
current treatment (1.80, 1.17 to 2.75), comorbidities
(eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular
disease/hypertension 1.69, 1.25 to 2.29) and moderate
or high SLE disease activity (vs remission; 1.61, 1.02
to 2.54 and 3.94, 2.11 to 7.34, respectively) were
associated with more severe..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.